Biofrontera Bioscience GmbH
🇩🇪Germany
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Phase 3
Recruiting
- Conditions
- Actinic Keratoses
- Interventions
- Combination Product: BF-200 ALA and red light LED lampCombination Product: Vehicle and red light LED lamp
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 165
- Registration Number
- NCT05662202
- Locations
- 🇺🇸
The Indiana Clinical Trials Center, PC, Plainfield, Indiana, United States
🇺🇸Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Alliance Dermatology & Mohs Center, Phoenix, Arizona, United States
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Phase 2
Recruiting
- Conditions
- Acne Vulgaris
- Interventions
- Combination Product: 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)Combination Product: 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 126
- Registration Number
- NCT05080764
- Locations
- 🇺🇸
DelRicht Research, Baton Rouge, Louisiana, United States
🇺🇸Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Cosmetic Laser Dermatology, San Diego, California, United States
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Phase 1
Completed
- Conditions
- Keratosis, ActinicActinic KeratosisKeratosis
- Interventions
- Combination Product: BF-200 ALA and red light LED lamp
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 112
- Registration Number
- NCT05060237
- Locations
- 🇺🇸
Clinical Research Center of the Carolinas, Charleston, South Carolina, United States
🇺🇸Laser and Skin Surgery Center of Indiana, Indianapolis, Indiana, United States
🇺🇸Dermatology Practice, Greenwood Village, Colorado, United States
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Phase 1
Completed
- Conditions
- Actinic Keratoses
- Interventions
- Combination Product: BF-200 ALA and red light LED lamp
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04319159
- Locations
- 🇺🇸
DermResearch Inc., Austin, Texas, United States
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
Phase 3
Active, not recruiting
- Conditions
- Superficial Basal Cell Carcinoma
- Interventions
- Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 186
- Registration Number
- NCT03573401
- Locations
- 🇺🇸
AboutSkin Research, LLC, Greenwood Village, Colorado, United States
🇺🇸University of Florida Dept of Dermatology, Gainesville, Florida, United States
🇺🇸The Narrows Institute for Biomedical Research and Education, Inc., Brooklyn, New York, United States
Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 122
- Registration Number
- NCT02799082
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Phase 3
Completed
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 571
- Registration Number
- NCT02799069
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
Phase 2
Completed
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 105
- Registration Number
- NCT02799030
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Phase 3
Completed
- Conditions
- Basal Cell Carcinoma (BCC)
- Interventions
- Drug: methyl-aminolevulinateDrug: BF-200 ALA
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 281
- Registration Number
- NCT02144077
- Locations
- 🇩🇪
Klinikum Vest GmbH, Recklinghausen, Westfalen-Lippe, Germany
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Phase 3
Completed
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Biofrontera Bioscience GmbH
- Target Recruit Count
- 87
- Registration Number
- NCT01966120
- Locations
- 🇩🇪
Dermatologisches Zentrum Bonn Friedensplatz, Bonn, Germany
© Copyright 2025. All Rights Reserved by MedPath